PharmAla licenses exclusive US rights to ALA-002 to Jupiter Neurosciences for up to US$100 million

• PharmAla licensed exclusive, perpetual U.S. rights to ALA-002 to Jupiter Neurosciences under a definitive agreement signed July 20, 2026.
• Total consideration up to about USD 100 million, including USD 3.33 million upfront paid in cash and Jupiter common stock.
• Milestones of up to USD 96.67 million tied to Phase 3 dosing, FDA approval, and U.S. sales thresholds up to USD 2 billion.
• A 3% royalty on U.S. net sales starts after the third commercialization milestone is achieved.
• PharmAla kept rights outside the U.S.; it will supply GMP-grade ALA-002 to Jupiter under a separate supply agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmala Biotech Holdings Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.